Therefore, therapeutic approaches that can diminish the availability of both AR-FL and AR-Vs should offer considerable benefit in preventing and inhibiting prostate cancer recurrence after androgen deprivation therapy. The gene discussed is AR; the disease is Familial prostate cancer.